| Enrolment (12 months) | Baseline | Follow-up (9 months from baseline) |
---|---|---|---|
Patients | |||
Review of inclusion criteria | X | Â | Â |
Informed consent signed | X | Â | Â |
Consent for involvement of family members | X | Â | Â |
Sociodemographic and clinical data | Â | X | Â |
Instruments | |||
Core set: PANSS, HAM-D, BRMRS, GAF, DAS | Â | X | X |
TIB, Life events (CECA-Q, PBI), neuropsychological tests (WCST, AX-CPT, WAIS) | Â | X | Â |
CDUS, PSYRATS, SAI-E, CAN-EU, WHOQOL-Bref, LEE | Â | X | X |
LCS, VSSS-EU | Â | Â | X |
SCAN | Â | Â | X |
Psychosocial/pharmacological treatment/admissions schedule | Â | Â | X |
VITreT | Â | Â | X |
Reporting of pharmacological side-effects and other adverse events | Â | X | X |
Family members | |||
Informed consent signed | X | Â | Â |
IEQ-EU, GHQ | Â | X | X |
PSA | Â | X | Â |
VSSS-Relatives | Â | Â | X |